



Published in final edited form as:

AIDS Behav. 2014 September ; 18(9): 1801–1807. doi:10.1007/s10461-014-0800-5.

Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study

Andrew Tomita^{1,2,3,*}, Nigel Garrett^{1,2}, Lise Werner^{1,2}, Jonathan K. Burns², Nelisiwe Ngcobo^{1,2}, Nomthandazo Zuma^{1,2}, Koleka Mlisana^{2,4}, Francois van Loggerenberg⁵, and Salim S. Abdool Karim^{1,2,3}

¹Centre for the AIDS Programme of Research in South Africa (CAPRISA)

²University of KwaZulu-Natal, Nelson R Mandela School of Clinical Medicine

³Columbia University Mailman School of Public Health

⁴Medical Microbiology Department, National Health Laboratory Service, Durban

⁵University of Oxford – The Global Health Network, Centre for Tropical Medicine

Abstract

Concerns are often raised regarding potentially adverse effects of antiretroviral therapy (ART) on health-related quality of life (HRQoL), but there is limited longitudinal data to prove this. Building on our prior investigation, we examined the impact of ART on HRQoL among HIV-infected South African women with extensive follow-up in the CAPRISA 002 Acute Infection Cohort Study. Overall HRQoL and five sub-domains [physical well-being (PWB), emotional well-being (EWB), functional and global well-being (FGWB), social well-being (SWB) and cognitive functioning (CF)] were assessed using the Functional Assessment of HIV Infection (FAHI) instrument. Our analyses comparing FAHI scores between pre-ART (established infection) and ART phases using paired Wilcoxon signed-rank tests and adjusted mixed-effects regression models revealed improvements on ART in overall HRQoL, and in PWB, EWB, and SWB, but not in FGWB and CF. No long-term adverse impact of ART on HRQoL was detected, providing additional non-biomedical support to early treatment strategies.

Keywords

Health-related quality of life; South Africa; Acute HIV infection; Functional assessment of HIV infection; ART

© Springer Science+Business Media New York 2014

*Corresponding author: Andrew Tomita, Ph.D., tomita@ukzn.ac.za, Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Private Bag X7, Congella, 4013, South Africa.

Preliminary data from this article was presented at the South African AIDS Conference in Durban, South Africa on June 19th 2013.

Conflict of interest: None.

Introduction

Given the recent breakthroughs in the use of antiretroviral therapy (ART) for HIV prevention [1] and early treatment [2], there is a growing focus on health-related quality of life (HRQoL) of individuals living with a life-long disease for which there is currently no cure. Rapid expansion of ART coverage in South Africa [3], the nation with the highest burden of HIV infection globally [4], not only means less infections to others through a reduced individual and community HIV viral load [5, 6], and the benefits of a stronger immune system to prevent co-infections such as tuberculosis [7], but also provides an opportunity for individuals to recover or even thrive after the devastating HIV diagnosis. While reducing viral load and the number of adverse events are key endpoints in ART studies, the HRQoL outcome is an important indicator of treatment adherence [8, 9] and the quality of health care delivery [10].

Health-related quality of life, a multi-dimensional and dynamic concept [11], reflects non-biomedical perspectives of HIV treatment, incorporating important subjective assessments on wide ranging aspects of individual well-being, including physical, functional, social, emotional [12] and even spiritual well-being [13] over time. While the scale-up of ART in KwaZulu-Natal province (KZN) has led to a dramatic increase in life expectancy [14], the question of long-term HRQoL benefits of ART remains debated and has seldom been investigated [15]. Few longitudinal studies, and even less recruiting at acute HIV infection, have been conducted in sub-Saharan Africa. In our previously published report in this journal [16], we used data from the CAPRISA 002 Acute Infection Study, a cohort study with extensive follow-up to assess HRQoL of HIV-positive South African women from acute infection up to ART initiation. Building on these investigations, here, we report on the long-term impact of ART on HRQoL among HIV-infected women from the CAPRISA 002 study.

Methods

Study Population

The CAPRISA 002 Acute HIV infection study is an ongoing prospective cohort study in KZN, South Africa. The study [17], which started recruitment in 2004, enrolled a cohort of HIV uninfected women 18 years and older with the aim to investigate the natural history of HIV-1 subtype C infection. Study participants were recruited at two sites: Durban, the largest city in KZN; and Vulindlela, a rural community located north-west of Durban. Participants were followed up for up to 4 years. Those who acquired HIV were enrolled into the acute infection stage (Phase II). Women who seroconverted in other CAPRISA prevention trials [18] also entered the CAPRISA 002 study at Phase II. Acute HIV infection status of all study participants was established based on a positive HIV antibody status with a documented HIV negative antibody test within 5 months of study enrollment or by plasma HIV-1 RNA testing using Amplicor or TaqMan (Roche Diagnostics, Rotkreuz, Switzerland) prior to seroconversion. Testing procedures of the CAPRISA 002 study have been described previously in detail [19].

Participants enrolled in the acute infection study completed a baseline acute infection assessment immediately after HIV diagnosis and were then followed-up for a maximum of 9 years at the time of our analysis. The follow-up assessment phase was classified as follows: acute infection (Phase II ≤ 3 months, but excluding the baseline assessment), early infection (Phase III >3 –12 months), established infection (Phase IV >12 months post-enrolment) and on ART (Phase V). Fifty-one of 160 participants initiated ART (referred to hereafter as the ART cohort) according to the South African Adult HIV Treatment Guidelines [20]. All participants received reimbursement for their time and travel expense for each assessment. Following diagnosis, post-HIV/sexually transmitted infection risk-reduction counselling, as well as ART treatment education, was available to study participants. Condoms were provided on request, and those requiring clinical care received it at the CAPRISA clinical research site, or at a specialist treatment centre where necessary. The Biomedical Research Ethics Committee of the University of KwaZulu-Natal approved the study.

Measures

The outcome data were obtained by trained research nurses throughout the study. The Functional Assessment of HIV Infection (FAHI) instrument was used to measure self-reported HRQoL, and was assessed at baseline, month three and bi-annually. The FAHI was designed to assess HRQoL of individuals living with HIV/AIDS and its reliability and validity has been established [21, 22]. It contains 44 items consisting of five subscales: physical well-being (PWB) (10 items), emotional well-being (EWB) (10 items), functional and global well-being (FGWB) (13 items), social well-being (SWB) (8 items), and cognitive functioning (CF) (3 items). Each item is rated on a 5-point ordinal scale of 0 (not at all) to 4 (very much). Higher FAHI scores reflect greater HRQoL. The Cronbach alpha internal consistency coefficient for the overall FAHI of the ART cohort was 0.90. Consistency coefficients for the PWB, EWB, FGWB, SWB, as well as the CF sub-scales were 0.92, 0.80, 0.83, 0.73 and 0.60, respectively.

The main exposure of our study is ART treatment initiation. The date of ART treatment initiation was obtained through patient chart review (with the permission of the participant). The study also assessed HIV knowledge, frequency of unprotected sexual practices, and the number of casual partners, irrespective of marital status at each visit via self-report. For unprotected sexual practices, risky sexual behavior was dichotomized as either high risk if the study participant self-reported sex without the use of a condom every time, or no/low risk for having no sex or sex with a condom being used every time. While we recognize that many study participants might utilize condoms sometimes, its consistent use is not only part of recommended practice by the US Center for Disease Control and Prevention [23], but also shown to substantially reduce HIV infection according to a meta-analysis [24]. In addition to face-to-face interviews, measurements for body mass index (BMI) and blood tests, including viral load and CD4, were obtained during the routine clinical assessments at every study visit.

Data Analysis

Descriptive statistics were used to summarize the demographic characteristics of the ART cohort. The differences in baseline demographic characteristics between the ART and non-

ART cohort was assessed using either Chi square (χ^2), student's *t* test or Wilcoxon rank-sum test. To assess associations between ART and HRQoL, FAHI scores pre-ART during established infection were compared to FAHI scores on ART using paired Wilcoxon signed-rank tests. The proportion of study participants above the minimally important differences (MID) threshold was calculated using the standard deviation (SD) method [25]. Under this method, the threshold is half the SD of the baseline score, which is defined as the closest FAHI score prior to ART initiation in our study context. The last observed FAHI score during the ART phase was the end point in this analysis. Therefore, a study participant was considered to have achieved minimally important improvement when the end point FAHI score was greater than the threshold. Linear mixed effects regression models were fitted to longitudinal FAHI scores to assess trends over time since ART referral, adjusting for demographic, HIV behavioral risk and clinical factors. Separate regression models were fitted for overall FAHI and five different sub-domains. To avoid over-adjustment bias related to controlling for intermediate variables on the causal pathway [26], viral load and CD4 were not included in the models (referred to hereafter as main models). Separate analyses were conducted to assess whether CD4 and viral load were effect modifiers in the relationship between ART and overall FAHI and five different sub-domains outcomes. All analyses were conducted using STATA version 13 (StataCorp, College Station, TX, USA).

Results

Characteristics of ART Cohort at Enrolment

All participants (Table 1) were black South African women ($n = 51$) with a mean age of 25.9 years (range 18–43). Approximately 75 % were married or had a stable partnership, and over half (54.9 %) reported having completed grades 11 or 12 of schooling. Thirty-one women (60.8 %) had at least one child who was financially dependent, and seven (13.7 %) disclosed being engaged in sex work. The majority of participants (82.4 %) had knowledge of HIV transmission and over half (54.9 %) were considered to be overweight/obese based on BMI measurement. The mean CD4 count was 488 cells/mm³ (range 229–1,358), and median log viral load was 4.7 copies/ml (IQR 4.2–5.1) at enrollment. The median number of days between baseline and referral for ART initiation was 638 days.

The group comparison assessment of baseline characteristics indicates that marital status ($\chi^2 = 6.78, p = 0.03$), presence of casual partners ($\chi^2 = 7.64, p < 0.01$) and educational attainment ($\chi^2 = 10.49, p = 0.01$) were significantly associated with ART initiation status. Lower baseline CD4 ($t = 3.18, p < 0.01$) and higher log viral load ($p < 0.01$) were detected among the ART-cohort compared ($n = 51$) to non-ART cohort ($n = 109$).

Overall and Subscale FAHI Score Comparisons Between Established Infection and ART Phase

Comparison of FAHI scores between pre-ART (established infection) and ART phases using paired Wilcoxon signed-rank tests (Table 2) showed that overall ($z = -3.6, p < 0.01$), PWB ($z = -3.0, p < 0.01$), EWB ($z = -3.8, p < 0.01$), and SWB ($z = -2.8, p < 0.01$) were significantly higher on ART compared to the established infection phase. No significant difference between phases was detected in FGWB and CF. The proportion of study

participants meeting meaningful HRQoL improvements in overall, PWB, EWB, FGWB, SWB and CF were 39, 30, 30, 20, 36 and 32 %, respectively (Table 2).

Health-Related Quality of Life Ratings Over Time from ART Referral

The adjusted linear mixed effects regression models (Table 3), similar to the Wilcoxon signed-rank tests, showed that ART was associated with higher levels of overall HRQoL ($\beta = 12.31, p < 0.01$), and of PWB ($\beta = 2.73, p = 0.03$), EWB ($\beta = 2.72, p = 0.03$), and SWB sub-domains ($\beta = 3.81, p < 0.01$). Stable partnership, as compared to multiple partnerships, was also a significant positive predictor of various aspects of HRQoL [overall ($\beta = 14.13, p = 0.03$), PWB ($\beta = 6.20, p = 0.01$), FGWB ($\beta = 4.28, p = 0.03$) and CF ($\beta = 1.88, p = 0.04$)]. The assessment of the time trend variable from the same regression models indicated that overall and FAHI sub-scale remained stable since ART referral. The assessment of the interaction term in separate models indicated that CD4 was an effect modifier of the relationship between ART and EWB ($\beta = 0.81, p = 0.04$), as well as CF ($\beta = -0.48, p < 0.01$) outcomes, but not in other sub-domains. The exposure to ART was an independent predictor of (only) CF after adjusting for interaction terms ($\beta = 3.74, p < 0.01$).

Discussion

Our study found an improvement in overall HRQoL, PWB, EWB, and SWB on ART and no negative impact on FGWB and CF. Approximately one-third of participants showed meaningful long-term HRQoL improvements from the time of ART referral. No adverse impact of ART on HRQoL was detected.

While our findings are consistent with other quality of life studies that detected positive treatment outcomes in physical [27–30], emotional/mental [27, 29, 31–33], and social well-being [29, 32, 34], some studies raise concerns over potential negative consequences of ART on HRQoL, including possible short-term adverse drug reactions [35], which may explain the decline in well-being domains in certain studies [33, 36]. In addition, fear of stigma and social discrimination [37–41] associated with ART treatment disclosure may negatively influence the quality of social relationships and general well-being. While adverse effects and stigma are major concerns in HIV treatment, medical interventions as well as perceptions of the disease evolve over time with education and public awareness. Our study did not detect any detrimental impact of ART, and it is possible, that newer ART regimens are better tolerated, which may account for the lack of decline in PWB in our study, although the role and availability of post-HIV counselling and ART clinical treatment guidance for our participants cannot be discounted.

Notably, a South African qualitative study of ART-related stigma indicated a positive life outlook facilitated by treatment literacy courses and treatment support groups involving patient, peers and family members at clinics [42]. These networks provided supportive environments and lessened the experiences of isolation, fear and stress among study participants. Thus, the counseling and treatment advice available in the study may partially account for observed improvements in social relations. While disclosure of ART may lower the quality of social relations and induce stigma, based on our findings, we generally concur

with the World Health Organization's [43] statement that attitudes towards HIV can change, and stigma can be reduced given that the disease is preventable and treatable with ART.

While our study did not detect ART-related improvements in FGWB and CF from the time of ART referral, this finding should be interpreted with some caution. Cognitive decline is known to accompany HIV progression, a finding detected in our previous investigation of the natural history of HIV 1 subtype C infection in ART-naïve women with extensive follow-up after acute infection [16]. In our current study, however, CF exhibited a non-monotonic shape, indicating initial stabilization and later rebounding, a finding consistent with a systematic review suggesting only partial improvement in neurocognitive function due to ART [44]. Lastly, FGWB, measuring performance of normal activities and overall feelings of well-being, (including hope and outlook for the future), remained stable from the time of ART referral. This may signal uncertainty towards the future among those on ART, and it justifies the need for supportive environments accompanying any ART scale-up initiatives. The overall ART-related improvement or stabilization on HRQoL warrants strengthening and further improvement of access to such life-saving services.

Nevertheless, the study had some limitations. Firstly, the relatively small sample of the ART cohort warrants some caution with regards to the interpretation. In particular, the observed association between ART and CF, may not be generalizable, requiring further studies with a larger cohort size of patients on ART. Secondly, the study was limited by not systematically measuring adherence to ART. While improvements in HRQoL are believed to be correlated with treatment adherence, it is possible that there is a delayed effect. The lack of adherence data, such as pill count, did not permit us to employ regression models to better capture causal inference between ART and HRQoL. Despite of these limitations, our results suggest that HRQoL among HIV-infected women either improved or stabilized on ART. Given that we did not detect a negative impact of ART on quality of life, this study provides additional non-biomedical support to early treatment strategies.

Acknowledgments

We thank all the CAPRISA 002 study participants who are making an important personal contribution to HIV research through their continued support and participation in our work. The scientific and supportive role of the whole CAPRISA 002 study and protocol team is gratefully acknowledged. Dr. Tomita was supported by the National Institutes of Health Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Eye Institute, National Heart, Blood, and Lung Institute, National Institute of Dental & Craniofacial Research, National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases Health, and NIH Office of Women's Health and Research through the International Clinical Research Fellows Program at Vanderbilt University (R24 TW007988) and the American Recovery and Reinvestment Act. Centre for the AIDS Programme of Research in South Africa (CAPRISA) received support for the CAPRISA 002 Acute Infection Study from the Comprehensive International Program of Research on AIDS (CIPRA) funded by the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) and the US Department of Health and Human Services (1 U19 AI51794).

References

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012; 367:399–410. [PubMed: 22784037]
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.* 2011; 365:493–505. [PubMed: 21767103]

3. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. *PLoS One*. 2010; 5:e11094. [PubMed: 20559425]
4. National Department of Health. National antenatal sentinel HIV & syphilis prevalence survey in South Africa, 2011. Republic of South Africa: Department of Health; 2012.
5. Tanser F, Barnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. *Science*. 2013; 339:966–71. [PubMed: 23430656]
6. Miller WC, Powers KA, Smith MK, et al. Community viral load as a measure for assessment of HIV treatment as prevention. *Lancet Infect Dis*. 2013; 13:459–64. [PubMed: 23537801]
7. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. *Chest*. 2002; 122:597–602. [PubMed: 12171838]
8. Jayaweera D, DeJesus E, Nguyen KL, et al. Virologic suppression, treatment adherence, and improved quality of life on a once-daily Efavirenz-based regimen in treatment-naïve HIV-1-infected patients over 96 weeks. *HIV Clin Trials*. 2009; 10:375–84. [PubMed: 20133268]
9. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. *AIDS Care*. 2005; 17:10–22. [PubMed: 15832830]
10. Dennison CR. The role of patient-reported outcomes in evaluating the quality of oncology care. *Am J Manag Care*. 2002; 8:S580–6. [PubMed: 12512982]
11. Sprangers MAG, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. *Soc Sci Med*. 1999; 48:1507–15. [PubMed: 10400253]
12. Healthy People 2020. Health-related quality of life and well-being. Washington, DC: US Department of Health and Human Services; 2013.
13. Daaleman TP, Frey BB. The spirituality index of well-being: a new instrument for health-related quality-of-life research. *Ann Fam Med*. 2004; 2:499–503. [PubMed: 15506588]
14. Bor J, Herbst AJ, Newell ML, et al. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. *Science*. 2013; 339:961–5. [PubMed: 23430655]
15. Burgoyne RW, Rourke SB, Behrens DM, et al. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. *AIDS Behav*. 2004; 8:151–63. [PubMed: 15187477]
16. Tomita A, Garrett N, Werner L, et al. Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study. *AIDS Behav*. 2014; 18:1114–23. [PubMed: 24368630]
17. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. *PLoS One*. 2012; 3:e1954. [PubMed: 18414658]
18. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science*. 2010; 329:1168–74. [PubMed: 20643915]
19. Mlisana K, Sobieszczyk M, Werner L, et al. Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. *PLoS One*. 2013; 8:e62928. [PubMed: 23646162]
20. National Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents, 2010. Republic of South Africa: Department of Health; 2010.
21. Cella DF, McCain NL, Peterman AH, et al. Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. *Qual Life Res*. 1996; 5:450–63. [PubMed: 8840825]
22. Peterman AH, Cella D, Mo F, et al. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. *Qual Life Res*. 1997; 6:572–84. [PubMed: 9330556]
23. Centers for Disease Control and Prevention. Condom fact sheet in brief. US Department of Health and Human Services; Atlanta, GA: 2013. <http://www.cdc.gov/condomeffectiveness/docs/CondomFactsheetInBrief.pdf>

24. Weller S, Davis-Beatty K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev.* 2002; 1:CD003255. [PubMed: 11869658]
25. Sloan J, Symonds T, Vargas-Chanes D, et al. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. *Drug Inf J.* 2003; 37:23–31.
26. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology.* 2009; 20:488–95. [PubMed: 19525685]
27. Booyesen, FIR; Rensburg, HV.; Bachmann, M., et al. The heart in HAART: quality of life of patients enrolled in the public sector antiretroviral treatment programme in the Free State province of South Africa. *Soc Indic Res.* 2007; 81:283–329.
28. Louwagie G, Bachmann M, Meyer K, et al. Highly active anti-retroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: a cross-sectional analytical study. *BMC Public Health.* 2007; 7:244. [PubMed: 17854510]
29. Stangl AL, Wamai N, Mermin J, et al. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. *AIDS Care.* 2007; 19:626–36. [PubMed: 17505923]
30. Rosen S, Kethlhapile M, Sanne I, et al. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. *AIDS.* 2008; 22:S131–9. [PubMed: 18664945]
31. Jelsma J, MacLean E, Hughes J, et al. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. *AIDS Care.* 2005; 17:579–88. [PubMed: 16036244]
32. Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2003; 32:38–47. [PubMed: 12514412]
33. Liu C, Ostrow D, Detels R, et al. Impacts of HIV infection and HAART use on quality of life. *Qual Life Res.* 2006; 15:941–9. [PubMed: 16900275]
34. Liu C, Weber K, Robison E, et al. Assessing the effect of HA-ART on change in quality of life among HIV-infected women. *AIDS Res Ther.* 2006; 3:6. [PubMed: 16549012]
35. Max B, Sherer R. Management of the adverse effects of anti-retroviral therapy and medication adherence. *Clin Infect Dis.* 2000; 30:S96–116. [PubMed: 10860894]
36. Gill CJ, Griffith JL, Jacobson D, et al. Relationship of HIV viral Loads, CD4 Counts, and HAART use to health-related quality of life. *J Acquir Immune Defic Syndr.* 2002; 30:485–92. [PubMed: 12154339]
37. Balcha TT, Jeppsson A, Bekele A. Barriers to antiretroviral treatment in Ethiopia: a qualitative study. *J Int Assoc Physicians AIDS Care (Chic).* 2011; 10:119–25. [PubMed: 21317162]
38. Nachega JB, Stein DM, Lehman DA, et al. Adherence to anti-retroviral therapy in HIV-infected adults in Soweto, South Africa. *AIDS Res Hum Retroviruses.* 2004; 20:1053–6. [PubMed: 15585095]
39. Dahab M, Charalambous S, Hamilton R, et al. “That is why I stopped the ART”: patients’ & providers’ perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. *BMC Public Health.* 2008; 8:63. [PubMed: 18282286]
40. Roura M, Urassa M, Busza J, et al. Scaling up stigma? The effects of antiretroviral roll-out on stigma and HIV testing. Early evidence from rural Tanzania. *Sex Transm Infect.* 2009; 85:308–12. [PubMed: 19036776]
41. Maughan-Brown B. Stigma rises despite antiretroviral roll-out: a longitudinal analysis in South Africa. *Soc Sci Med.* 2010; 70:368–74. [PubMed: 19892454]
42. Zuch M, Lurie M. ‘A virus and nothing else’: the effect of ART on HIV-related stigma in rural South Africa. *AIDS Behav.* 2012; 16:564–70. [PubMed: 22080386]
43. World Health Organization. *Treating 3 million by 2005—making it happen: the WHO strategy.* Geneva: 2003.
44. Joska JA, Gouse H, Paul RH, et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. *J Neurovirol.* 2010; 16:101–14. [PubMed: 20345318]

Table 1

Baseline characteristics of ART cohort in the CAPRISA 002 study at enrollment (n = 160)

Variable	ART cohort (n = 51)		ART not-initiated (n = 109)		Statistics, p
	n	%	n	%	
Age groups					
18–20	11	21.6 %	17	15.6 %	$\chi^2 = 8.81, 0.07$
21–24	17	33.3 %	44	40.4 %	
25–29	10	19.6 %	31	28.4 %	
30–39	12	23.5 %	10	9.2 %	
40–59	1	2.0 %	7	6.4 %	
Race					$\chi^2 = 0.47, 0.49$
Black	51	100.0 %	108	99.1 %	
Marital status					$\chi^2 = 6.78, 0.03$
Married ^b /stable partnership ^c	38	74.5 %	82	75.2 %	
Many partners	7	13.7 %	4	3.7 %	
No partner—single	6	11.8 %	23	21.1 %	
Presence of casual partners					$\chi^2 = 7.64, <0.01$
Yes	14	27.5 %	11	10.3 %	
Highest completed education					$\chi^2 = 10.49, <0.01$
Less than high school < 8th grade	2	3.9 %	5	4.6 %	
High school up to 10th grade	21	41.2 %	19	17.4 %	
At least Grade 11/12	28	54.9 %	85	78.0 %	
Contraception use					$\chi^2 = 3.53, 0.06$
Yes	36	70.6 %	91	83.5 %	
Knowledge of HIV					$\chi^2 = 2.38, 0.12$
Yes	42	82.4 %	99	90.8 %	
Sex work					$\chi^2 = 1.81, 0.18$
Yes	9	17.7 %	11	10.1 %	
BMI					$p = 0.39$ ^d
Underweight	2	3.9 %	2	1.8 %	
Normal	21	41.2 %	37	33.9 %	
Overweight/obese	28	54.9 %	70	64.2 %	
CD4 count ^d					$t = 3.18, <0.01$
Cells per mm ³	M = 488.02	SD = 203.2	M = 606.89	SD = 219.4	
Log viral load ^d					$p < 0.01$ ^e
Copies/mL	Mdn = 4.7	IQR = 4.2–5.1	Mdn = 4.1	IQR = 3.3–4.8	

^a 3-month post infection

^b Marriage based on customary, religious or civil marriage/union

^c Stable partnership defined as having one regular partner but not necessary falling under solemnization category of customary, religious or civil marriage/ union

^d Based on Fisher's exact test

^e Based on rank-sum test

Table 2

Pre- and post-ART HRQoL rating and minimally important difference (MID)

Domains	Established infection phase		ART phase		Phase comparison		MID score	Number of participants meeting threshold $T_2 > T_1$
	Median score		Median score		z	p		
Overall (0–176)	160.5		168.8		-3.6	<0.001	14.6	17 (38.6%)
Physical well-being (0–40)	38.5		39.9		-3.0	<0.01	4.8	13 (29.6%)
Emotional well-being (0–40)	35		37.3		-3.8	<0.001	4.7	13 (29.6%)
Functional/global well-being (0–52)	51		51		-0.6	0.52	4.6	9 (20.5%)
Social well-being (0–32)	28		30		-2.8	<0.01	3.8	16 (36.4%)
Cognitive functioning (0–12)	11		11.6		-1.9	0.06	1.4	14 (31.8%)

 z and p value based on Wilcoxon sign-rank pair for phase comparisons

MID minimally importance difference

 T_2 FAHI score prior to ART phase—last FAHI score during ART phase

Table 3
Trend analysis for overall FAHI and sub-scale outcomes using adjusted mixed-effects models since the time of ART referral

	Overall FAHI			PWB			EWB			FGWB			SWB			CF		
	β	SE	p	β	SE	p	β	SE	p	β	SE	p	β	SE	p	β	SE	p
ART	12.31	3.35	<0.01	2.73	1.23	0.03	2.72	1.24	0.03	1.36	1.03	0.19	3.81	1.12	<0.01	0.68	0.43	0.12
Days since ART referral	<-0.01	<0.01	0.67	<-0.01	<0.01	0.72	<0.01	<0.01	0.74	<-0.01	<0.01	0.70	<-0.01	<0.01	0.71	<0.01	<0.01	0.78
Age category																		
21-24	-0.92	3.95	0.82	-0.54	1.44	0.71	-0.41	1.68	0.81	2.09	1.20	0.08	-3.82	1.41	0.01	-0.49	0.64	0.45
25-29	3.58	4.99	0.47	1.32	1.80	0.47	1.87	2.02	0.36	2.21	1.51	0.14	-2.97	1.71	0.08	-0.28	0.66	0.67
30-39	9.25	5.42	0.09	3.74	1.96	0.06	2.85	2.18	0.19	2.83	1.63	0.08	-2.26	1.87	0.23	0.19	0.72	0.80
40-59	-4.23	9.40	0.65	0.25	3.49	0.94	3.83	3.73	0.31	-0.64	2.84	0.82	-10.58	3.36	0.00	-1.80	1.41	0.20
Education																		
School grade < 8	-12.76	8.51	0.13	-3.55	3.08	0.25	0.26	3.41	0.94	-5.00	2.57	0.05	-1.30	2.88	0.65	-0.43	1.14	0.71
School 8-10	-2.80	3.13	0.37	1.20	1.05	0.25	-2.06	1.30	0.11	-0.83	0.88	0.35	-0.49	1.08	0.65	0.10	0.38	0.80
Marital status																		
Married/stable partner	14.13	6.60	0.03	6.20	2.39	0.01	2.41	2.70	0.37	4.28	1.99	0.03	-0.65	2.23	0.77	1.88	0.89	0.04
Single	17.34	5.30	<0.01	3.34	1.92	0.08	4.39	2.19	0.05	3.29	1.59	0.04	3.35	1.82	0.07	1.59	0.71	0.03
Knowledge of HIV																		
Yes	-1.24	4.27	0.77	0.76	1.56	0.63	2.23	1.71	0.19	-0.33	1.29	0.80	-2.18	1.44	0.13	-0.70	0.58	0.22
Sex worker status																		
Yes	4.26	3.90	0.27	-0.63	1.40	0.65	1.15	1.66	0.49	1.63	1.17	0.17	1.13	1.36	0.41	-0.68	0.54	0.20
Casual partner																		
Present	0.14	6.47	0.98	1.82	2.33	0.43	-0.29	2.35	0.90	0.40	1.94	0.84	-3.25	2.18	0.14	1.06	0.83	0.20
BMI																		
Underweight	-9.94	15.14	0.51	-4.59	5.46	0.40	-1.66	5.46	0.76	-2.55	4.57	0.58	0.44	5.06	0.93	1.45	1.92	0.45
Overweight/obese	-1.97	3.00	0.51	0.89	1.11	0.42	-1.70	1.19	0.15	0.15	0.94	0.87	0.00	1.00	1.00	0.79	0.39	0.05
Peno-vaginal sex act ^d																		
High risk	-3.32	4.98	0.51	-0.06	1.80	0.97	0.46	1.80	0.80	0.21	1.50	0.89	-3.64	1.68	0.03	-0.58	0.64	0.37
Oral sex act ^d																		
High risk	11.31	10.69	0.29	2.08	3.85	0.59	-0.32	3.79	0.93	2.05	3.22	0.52	4.84	3.66	0.19	-0.14	1.36	0.92
Sex act under influence of alcohol ^d																		

	Overall FAHI			PWB			EWB			FGWB			SWB			CF		
	β	SE	<i>p</i>	β	SE	<i>p</i>	β	SE	<i>p</i>	β	SE	<i>p</i>	β	SE	<i>p</i>	β	SE	<i>p</i>
High risk	12.50	8.11	0.12	1.57	2.93	0.59	2.92	2.97	0.33	2.60	2.44	0.29	4.38	2.74	0.11	-0.14	1.05	0.89

^aTime covariant. Reference category: Age [18–20], education [grade>10], marital status [many partners], BMI [normal], and sex (peno-vaginal, oral and under influence of alcohol) act [no or low risk since condoms used]

β estimate, SE standard error, PWB physical well-being, EWB emotional well-being, FGWB functional/global well-being, SWB social well-being, CF cognitive functioning